CAMBRIDGE, Mass. — September 10, 2025 — Leads & Copy — Ernexa Therapeutics (Nasdaq: ERNA) announced an update on its operational excellence and performance for the first half of 2025, reporting financial results in its Quarterly Report on Form 10-Q for the period ending June 30, 2025.
The company, which is developing innovative cell therapies for advanced cancer and autoimmune disease, filed the report with the Securities and Exchange Commission on August 13, 2025. Improvements were attributed to focused execution and cost discipline as ERNA-101 for ovarian cancer, and ERNA-201 for autoimmune disease advance.
Ernexa is advancing a best-in-class approach using synthetic, allogeneic induced mesenchymal stem cells (iMSCs) to provide a scalable, off-the-shelf treatment without needing patient-specific cell harvesting. The company’s two highly innovative cell therapy products, focused on targeting ovarian cancer and autoimmune disease, are currently advancing through preclinical stages.
Operational milestones achieved during the first half of this year include:
Operating loss decreased by $5.5 million, or 51%, from $10.7 million during the six months ending on June 30, 2024 to $5.2 million during the six months ending on June 30, 2025.
Total operating expenses decreased by $5.4 million, or 51%, from $10.6 million during the six months ending on June 30, 2024 to $5.2 million during the six months ending on June 30, 2025.
General and administrative expenses decreased by $5.4 million, or 66%, from $8.2 million during the six months ending on June 30, 2024 to $2.8 million during the six months ending on June 30, 2025.
Total lease expense decreased by $3.8 million, or 97%, from $3.9 million during the six months ending on June 30, 2024 to $0.1 million during the six months ending on June 30, 2025, primarily reflecting the termination of a sublease.
“These first half results reflect the discipline we’ve brought to the business. We are operating leaner, prioritizing the programs that matter the most, and positioning Ernexa to execute and thrive,” said Sanjeev Luther, President and CEO of Ernexa Therapeutics. “With our operating expenses down by 51% compared to last year, as well as a streamlined cost structure, we believe we have the right foundation to advance our cell therapies toward the clinical stage and continue building a durable company that can deliver off-the-shelf cell therapies to patients who need better options.”
Media & Investor Relations Contact:
investors@ernexatx.com
Source: Ernexa Therapeutics
